Literature DB >> 10651142

Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors.

M Nakazi1, U Bauer, T Nickel, M Kathmann, E Schlicker.   

Abstract

We studied whether serotonin release in the CNS is inhibited via cannabinoid receptors. In mouse brain cortex slices preincubated with [3H]serotonin and superfused with medium containing indalpine and metitepine, tritium overflow was evoked either electrically (3 Hz) or by introduction of Ca2+ (1.3 mM) into Ca2+-free K+-rich (25 mM) medium containing tetrodotoxin. The effects of cannabinoid receptor ligands on the electrically evoked tritium overflow from mouse brain cortex slices preincubated with [3H]choline and on the binding of [3H]WIN 55,212-2 and [35S]GTPgammaS to mouse brain cortex membranes were examined as well. In superfused mouse cortex membranes preincubated with [3H]serotonin, the electrically evoked tritium overflow was inhibited by the cannabinoid receptor agonist WIN 55,212-2 (maximum effect of 20%, obtained at 1 microM; pEC50=7.11) and this effect was counteracted by the CB1 receptor antagonist SR 141716 (apparent pA2=8.02), which did not affect the evoked tritium overflow by itself. The effect of WIN 55,212-2 was not shared by its enantiomer WIN 55,212-3 but was mimicked by another cannabinoid receptor agonist, CP-55,940. WIN 55,212-2 also inhibited the Ca2+-evoked tritium overflow and this effect was antagonized by SR 141716. Concentrations of histamine, prostaglandin E2 and neuropeptide Y, causing the maximum effect at their respective receptors, inhibited the electrically evoked tritium overflow by 33, 69 and 73%, respectively. WIN 55,212-2 (1 microM) inhibited the electrically evoked tritium overflow from mouse brain cortex slices preincubated with [3H]choline by 49%. [3H]WIN 55,212-2 binding to mouse cortex membranes was inhibited by CP-55,940, SR 141716 and WIN 55,212-2 (pKi=9.30, 8.70 and 8.19, respectively) but not by the auxiliary drugs indalpine, metitepine and tetrodotoxin (pKi<4.5). [35S]GTPgammaS binding was increased by WIN 55,212-2 (maximum effect of 80%, pEC50=6.94) but not affected by WIN 55,212-3. In conclusion, serotonin release in the mouse brain cortex is inhibited via CB1 receptors, which may be located presynaptically and are not activated by endogenous cannabinoids. The extent of inhibition is smaller than that obtained (1) via another three presynaptic receptors on serotoninergic neurones and (2) via CB1 receptors on cholinergic neurones in the same tissue.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10651142     DOI: 10.1007/s002109900147

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  46 in total

1.  Reflection impulsivity in adolescent cannabis users: a comparison with alcohol-using and non-substance-using adolescents.

Authors:  Nadia Solowij; Katy A Jones; Megan E Rozman; Sasha M Davis; Joseph Ciarrochi; Patrick C L Heaven; Nicole Pesa; Dan I Lubman; Murat Yücel
Journal:  Psychopharmacology (Berl)       Date:  2011-09-21       Impact factor: 4.530

2.  Alterations in behavioral flexibility by cannabinoid CB1 receptor agonists and antagonists.

Authors:  Matthew N Hill; Larissa M Froese; Anna C Morrish; Jane C Sun; Stan B Floresco
Journal:  Psychopharmacology (Berl)       Date:  2006-06-03       Impact factor: 4.530

Review 3.  Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.

Authors:  Tristram A Lett; Henrik Walter; Eva J Brandl
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

4.  Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial.

Authors:  Aimee L McRae-Clark; Nathaniel L Baker; Kevin M Gray; Therese K Killeen; Amanda M Wagner; Kathleen T Brady; C Lindsay DeVane; Jessica Norton
Journal:  Drug Alcohol Depend       Date:  2015-08-25       Impact factor: 4.492

5.  Haloperidol, but not clozapine, produces dramatic catalepsy in delta9-THC-treated rats: possible clinical implications.

Authors:  Giorgio Marchese; Paola Casti; Stefania Ruiu; PierLuigi Saba; Angela Sanna; GianLuca Casu; Luca Pani
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

6.  Cannabinoid Receptors, Mental Pain and Suicidal Behavior: a Systematic Review.

Authors:  Laura Colino; Javier Herranz-Herrer; Elena Gil-Benito; Teresa Ponte-Lopez; Pablo Del Sol-Calderon; Maria Rodrigo-Yanguas; María Gil-Ligero; Antonio J Sánchez-López; Jose de Leon; Hilario Blasco-Fontecilla
Journal:  Curr Psychiatry Rep       Date:  2018-03-15       Impact factor: 5.285

Review 7.  Role of endocannabinoid system in mental diseases.

Authors:  Jorge Manzanares; Leyre Urigüen; Gabriel Rubio; Tomás Palomo
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 8.  Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate.

Authors:  K Rea; M Roche; D P Finn
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

9.  Effect of the CB1 cannabinoid agonist WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference in mice.

Authors:  Carmen Manzanedo; Marta Rodríguez-Arias; Manuel Daza-Losada; Concepción Maldonado; María A Aguilar; José Miñarro
Journal:  Behav Brain Funct       Date:  2010-03-22       Impact factor: 3.759

10.  PKCepsilon regulates behavioral sensitivity, binding and tolerance to the CB1 receptor agonist WIN55,212-2.

Authors:  Melisa J Wallace; Philip M Newton; Thomas McMahon; Jacklyn Connolly; Anne Huibers; Jennifer Whistler; Robert O Messing
Journal:  Neuropsychopharmacology       Date:  2009-01-21       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.